US FDA's Drug Seizures Seen As Most Significant Aspect Of Stem Cell Crackdown

Former Office of Compliance and Biologics Quality Deputy Director Mark Schwartz says dishonest players have not often seen serious enforcement actions from the agency.

Seizure of property. Yellow warning tapes with inscription "SEIZURE OF PROPERTY"

Stem cell manufacturers have rarely been subject to aggressive US FDA enforcement actions, but Commissioner Scott Gottlieb's recent announcement about a crackdown on unscrupulous companies in the regenerative medicine industry along with the seizure of product from a California facility could signal a meaningful change in how the agency targets dishonest industry players, a former FDAer says.

The Center for Biologics Evaluation and Research (CBER) has not often directed the seizure of unapproved product as it did in August with the confiscation of five vials of a live vaccinia virus vaccine at the California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif

More from Cell & Gene Therapies

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By 

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By 

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By 

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By 

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.

More from Advanced Technologies